Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells $27,479,532.79 in Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Amit Sachdev sold 58,613 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $468.83, for a total value of $27,479,532.79. Following the sale, the executive vice president owned 58,934 shares of the company’s stock, valued at approximately $27,630,027.22. The trade was a 49.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Amit Sachdev also recently made the following trade(s):

• On Wednesday, February 25th, Amit Sachdev sold 1,846 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $486.35, for a total transaction of $897,802.10.

Vertex Pharmaceuticals Trading Up 3.5%

VRTX stock opened at $496.83 on Monday. The stock has a market cap of $126.21 billion, a P/E ratio of 32.41 and a beta of 0.31. Vertex Pharmaceuticals Incorporated has a twelve month low of $362.50 and a twelve month high of $519.68. The company’s 50 day moving average is $466.55 and its two-hundred day moving average is $432.55.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.05 by ($0.02). Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The company had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.18 billion. During the same quarter in the previous year, the company posted $3.98 EPS. The company’s quarterly revenue was up 9.5% on a year-over-year basis. On average, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Chesapeake Asset Management LLC grew its holdings in shares of Vertex Pharmaceuticals by 110.0% in the 3rd quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock valued at $25,000 after buying an additional 33 shares during the period. Motiv8 Investments LLC acquired a new position in Vertex Pharmaceuticals in the fourth quarter valued at about $26,000. Access Investment Management LLC acquired a new position in Vertex Pharmaceuticals in the second quarter valued at about $27,000. Colonial Trust Co SC increased its holdings in shares of Vertex Pharmaceuticals by 118.8% in the third quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 38 shares in the last quarter. Finally, Swiss RE Ltd. acquired a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth about $28,000. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Clinical safety expansion — Vertex announced a new study to evaluate VX‑548 (an investigational pain drug) in breastfeeding women, broadening the drug’s safety profile and de‑risking development pathways if results are supportive. Vertex Expands VX‑548 Safety Profile With New Breastfeeding Study
• Positive Sentiment: Leadership/PR tailwind — TIME profiled CEO Reshma Kewalramani, reinforcing investor confidence in management’s execution and Vertex’s strategy to expand beyond cystic fibrosis. Physician‑Scientist Reshma Kewalramani Runs One of Biotech’s Biggest Companies
• Positive Sentiment: Analyst support — recent upgrades and raised price targets (several firms highlighted in coverage) help underpin the stock and attract buy‑side interest. MarketBeat VRTX analyst coverage
• Neutral Sentiment: Quarterly fundamentals — Q4 revenue rose ~9.5% y/y and margins remain strong, though EPS missed by $0.02 (reported $5.03 vs. $5.05 consensus); this is a small miss that keeps the longer‑term thesis intact but mutes near‑term upside. Vertex recent earnings summary
• Neutral Sentiment: Momentum/coverage — pieces asking whether VRTX is outperforming major indices may draw momentum flows but do not represent new fundamental catalysts. Is Vertex Stock Outperforming the Dow?
• Negative Sentiment: Clustered insider selling — multiple senior executives disclosed sales between Feb. 19–25, including a large sale by EVP Amit Sachdev (~58,613 shares, ~ $27.5M) and several other EVPs reducing positions. Such concentrated insider sales can create near‑term negative sentiment even if driven by diversification or tax planning. Representative SEC filing: SEC Form 4 – Amit Sachdev
• Negative Sentiment: Additional officer sale — CAO Kristen Ambrose sold 223 shares (minor relative to the EVP sales) but is part of the broader disclosure set that traders are reacting to. Vertex insider sales roundup

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on VRTX. Sanford C. Bernstein reissued an “outperform” rating and issued a $577.00 target price on shares of Vertex Pharmaceuticals in a research report on Friday, February 13th. Weiss Ratings upgraded Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, February 4th. Oppenheimer upgraded shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $540.00 target price on the stock in a research report on Friday, February 13th. Scotiabank lifted their target price on shares of Vertex Pharmaceuticals from $495.00 to $558.00 and gave the company an “outperform” rating in a report on Friday, February 13th. Finally, Royal Bank Of Canada reduced their price target on shares of Vertex Pharmaceuticals from $546.00 to $541.00 and set an “outperform” rating for the company in a research report on Friday, February 13th. Twenty-two research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $542.00.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.